Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma?
- PMID: 2069758
Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma?
Abstract
The combination of alpha interferon and vinblastine has been reported to yield a response rate of 30-40% in previously untreated patients with metastatic renal cell carcinoma. This combination was given to nine patients with advanced metastatic renal carcinoma after they failed or relapsed on alpha-interferon alone, to attempt to evaluate the role of vinblastine in this combination. Neither complete nor partial response was observed. Two patients had disease stabilization for two and seven months. Our preliminary results suggest that vinblastine did not add to the efficacy of interferon in this group of patients.
Similar articles
-
[Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].J Urol (Paris). 1987;93(8):463-6. J Urol (Paris). 1987. PMID: 3440838 French.
-
Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.Cancer Treat Rep. 1985 Mar;69(3):263-7. Cancer Treat Rep. 1985. PMID: 3978656
-
Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.J Biol Response Mod. 1990 Aug;9(4):439-44. J Biol Response Mod. 1990. PMID: 2395008
-
[Interferon-alpha therapy in hypernephroma].Wien Med Wochenschr. 1993;143(16-17):443-7. Wien Med Wochenschr. 1993. PMID: 8273370 Review. German.
-
Systemic therapy for renal cell carcinoma.J Urol. 2000 Feb;163(2):408-17. J Urol. 2000. PMID: 10647643 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical